PubMed Health⌕ Search

PubMed · 15836046

Time-dependent density functional theory study on intramolecular charge transfer and solvent effect of dimethylaminobenzophenone.

Abstract

The lower singlet excited states for dimethylaminobenzophenone have been investigated as a function of the twisting motion with inclusion of solvent effects. Theoretical calculations have been performed using time-dependent density functional theory. The B3LYP and MPW1PW91 functionals with a 6-311+G(2d,p) basis set have been used to compute transition energies. The solvent effects have been described within the polarizable continuum model. Ground-state geometries are optimized using density functional theory with both B3LYP and MPW1PW91 functionals combined with 6-31G(d) basis sets. Vertical absorption energy calculations characterize the lower singlet excited states both in vacuum and in different kinds of solvents. A large redshift of the absorption maximum in the polar solvent suggests an intramolecular charge transfer character of the excited state. We have constructed the potential energy curves of two possible twisting motions of the excited states both in vacuum and in the polar solvent of acetonitrile: the twisting of only the dimethylamino group and the twisting of the dimethylaminophenyl group with respect to the benzoyl group. Both twisting processes predict the formation of the twisted intramolecular charge transfer state associated with the crossing of a low barrier. The presence of the polar solvent significantly changes the shape of the energy curves. Calculated emission energies for both the isolated and the solvated systems show a large Stokes shift between the absorption and fluorescence maxima. Two possible twisting motions produce similar fluorescence spectroscopic consequences. Our results including solvent effects explain the weak "dual-fluorescence" feature of dimethylaminobenzophenone, and imply that the two possible twisting motions may occur in the excited-state relaxation dynamics, but the twisting of the dimethylamino group seems to take place easier.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Xiao-Hui Duan, Xiang-Yuan Li, Rong-Xing He, Xue-Mei Cheng. 2005-02-22. Time-dependent density functional theory study on intramolecular charge transfer and solvent effect of dimethylaminobenzophenone.. https://doi.org/10.1063/1.1850097

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗